Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Phase 1/2 Completed 17 enrolled LUCINDA BATEMAN, MD

Non-randomizedSequentialOpen-labelTreatment

Summary

This study seeks to investigate the safety, tolerability and efficacy of CT38, an experimental peptide administered by subcutaneous infusion, in the treatment of ME/CFS patients.

Timeline

Start: 2018-07-23
Primary completion: 2019-04-30
Completion: 2019-04-30

Publications

Pereira G, Gillies H, Chanda S, Corbett M, Vernon SD, Milani T, Bateman L. Acute Corticotropin-Releasing Factor Receptor Type 2 Agonism Results in Sustained Symptom Improvement in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front Syst Neurosci. 2021 Sep 1;15:698240. doi: 10.3389/fnsys.2021.698240. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	CT38	Peptide	0.01 ug/kg	Subcutaneous
Comparator	CT38	Peptide	0.03 ug/kg	Subcutaneous
Comparator	CT38	Peptide	0.06 ug/kg	Subcutaneous
Comparator	CT38	Peptide	0.2 ug/kg	Subcutaneous

Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Summary

Timeline

Publications

Drugs

Indications